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Abstract
Introduction—The National Institutes of Health (NIH) sees provider-based research networks
and other organizational linkages between academic researchers and community practitioners as
promising vehicles for accelerating the translation of research into practice. This study examines
whether organizational research affiliations and teaching affiliations are associated with
accelerated diffusion of sentinel lymph node biopsy (SLNB), an innovation in the treatment of
early-stage breast cancer.
Methods—Surveillance Epidemiology and End Results-Medicare data were used to examine the
diffusion of SLNB for treatment of early-stage breast cancer among women aged 65 years and
older diagnosed between 2000 and 2002, shortly after Medicare approved and began reimbursing
for the procedure.
Results—In this population, patients treated at an organization affiliated with a research network
—-the American College of Surgeons Oncology Group (ACOSOG) or other National Cancer
Institute (NCI) cooperative groups—-were more likely to receive the innovative treatment (SLNB)
than patients treated at unaffiliated organizations (odds ratio: 2.70, 95% confidence interval: 1.77–
4.12; odds ratio: 1.84, 95% confidence interval: 1.26–2.69, respectively). Neither hospital teaching
status nor surgical volume was significantly associated with differences in SLNB use.
Discussion—Patients who receive cancer treatment at organizations affiliated with cancer
research networks have an enhanced probability of receiving SLNB, an innovative procedure that
offers the promise of improved patient outcomes. Study findings support the NIH Roadmap and
programs such as the NCI’s Community Clinical Oncology Program, as they seek to accelerate the
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translation of research into practice by simultaneously accelerating and broadening cancer
research in the community.
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breast cancer; translational research; diffusion of innovation; organization and administration;
provider-based research networks
Scientific advances are rapidly reshaping cancer care. Much original research takes 17 years
before yielding patient care benefits,1 and so the accelerating pace of discovery places a
premium on the need for rapid translation of research into practice. The National Institutes
of Health has clearly recognized this need.2–5 As one means of addressing it, the National
Cancer Institute (NCI) has emphasized moving beyond traditional teaching systems by
linking academic centers to community practitioners who treat the majority of cancer
patients. For example, the NCI Community Clinical Oncology Program (CCOP) effectively
connects the NCI Cooperative Groups (researchers primarily at academic centers developing
and managing clinical trials) with a nationwide provider-based research network of
community physicians treating cancer patients and enrolling them on clinical trials.6 CCOP
organizational goals include not only enrolling patients on trials, but also accelerating the
diffusion of evidence-based innovations into practice, among others.2,6–10
Sentinel lymph node biopsy (SLNB) is an important innovation in breast cancer treatment.
In breast cancer, the presence or absence of cancer in the axillary lymph nodes is the most
important predictor of recurrence and death. On the basis of lymph node involvement,
treatment may variably include more extensive surgery, radiation therapy, or chemotherapy;
therefore, accurate assessment of lymph nodes is critical in determining the optimal
treatment plan.11,12 Axillary lymph node dissection (ALND) has long been an effective
means of assessing lymph node involvement and an integral part of treatment.13,14 ALND is
an extensive procedure in which 10 or more lymph nodes are removed and a surgical drain
is placed, followed by one or more night stays in a hospital. It is associated with
considerable surgical morbidity including lymphedema, nerve paresthesias, axillary
seromas, and infections.15 Several studies have demonstrated that a newer procedure,
SLNB, is a safe and accurate alternative for examining lymph nodes. SLNB and ALND are
equivalent in terms of disease control and patient survival. Because it necessitates removal
of only 1 to 3 nodes, SLNB is associated with substantially fewer and less severe
morbidities and commonly no overnight hospital stay.16–24 Accordingly, SLNB has been
widely adopted by surgeons as an innovative alternative to routine ALND for axillary
staging in early breast cancer.
As with many other innovations, adoption of SLNB has not been uniform.25 Factors
previously shown to be associated with variation in use of SLNB include patient
characteristics (eg, age, race, insurance coverage) and organizational factors (eg, surgical
volumes, being an NCI-designated cancer center).26–31 Although prior research has
established that these organizational characteristics are relevant, a more specific question
remains largely unanswered: Are organizational affiliations relating to teaching and research
associated with accelerated adoption of innovative breast cancer treatments? This study
examines the diffusion of SLNB among organizations providing breast cancer treatment,
and hypothesizes that research and teaching affiliation are associated with accelerated
innovation diffusion.
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This study is informed by diffusion theory,32,33 which posits the following 5 stages in the
innovation-decision process: knowledge, persuasion, decision, implementation, and
confirmation. In the knowledge stage, individuals are exposed to information regarding the
existence of an innovation, often through general or mass media. Progress through the
innovation-decision process is facilitated when the individual is receptive, the innovation
suits their norms, and the information is from a credible source. In the persuasion stage,
individuals assess the innovation’s relevance and potential advantage for themselves, and
form favorable or unfavorable attitudes, although decreasing their uncertainty about it. A
decision to adopt is facilitated through interpersonal communication among homophilous
peers exchanging personal experiences. It is more likely in the case of homophily and
greater exposure to advocates, including opinion leaders and early adopters who tend to be
more influenced by mass media and whose subsequent personal influence spreads the
innovation to their followers.32 Implementation allows first-hand evaluation and further
opportunity to reduce uncertainty about the innovation, particularly in a controlled
environment.
For this study, clinical communication channels comprise a baseline context. In this study,
all clinicians might be exposed to information about innovations through the mass media,
clinical media (eg, newsletters, journals), and their peers. Through these channels, exposure
to this information is comparatively passive, unfocused, and often unsolicited; however,
through these channels, individuals may first learn of innovations and choose to gather and
evaluate more information. With the passage of time, innovative treatments will diffuse,
perhaps slowly and unevenly, to community hospitals and practices through clinical
communication channels.
Organizations participating in graduate medical education are hypothesized to have more
effective pathways for innovation diffusion than those that do not. In the present study, local
thought leaders (eg, instructors) and information seekers (eg, interns, residents, and other
attending physicians) are commonly at these organizations due to their own interest and
motivation, and so exposure to information is both more active and more focused,
particularly within specialties and among those in later years of training. In addition,
knowledge of “the state-of-the-art” is encouraged and reinforced in these environments that
value communicating it through didactic, lecture-based, or practicum-based learning.
Therefore, community hospitals and practices that are organizationally linked to academic
centers through teaching relationships will experience innovation diffusion more quickly
than those with no such linkages.
Organizations affiliated with clinical research networks like the American College of
Surgeons Oncology Group (ACOSOG) or other NCI cooperative groups are hypothesized to
have even more effective pathways for innovation diffusion. Through research meeting
attendance, community practitioners gain access to the latest scientific findings before
publication. In addition, through social interaction, academic researchers and receptive
community practitioners can exchange information about the innovative relevance and
potential advantages of the treatment. Finally, direct participation in the clinical research
sponsored by the networks affords community practitioners opportunity to gain first-hand
experience with the innovation. Therefore, organizations that participate in clinical research
networks are likely to adopt innovative treatments faster than those that participate in
teaching networks or those that receive information primarily through clinical
communication channels.
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Data are from the Surveillance Epidemiology and End Results (SEER)-Medicare linked
data, which have been previously described.34 Briefly, SEER-Medicare is a collaborative
effort between the NCI and Centers for Medicare and Medicaid Services (CMS), which
links routinely collected population-based data from cancer registries across the country to
Medicare administrative data and health care claims. The SEER data include demographic
and incident cancer characteristics including grade and stage, as well as treatment
information and vital status for approximately 25% of the US cancer population. Medicare
provides health insurance for 97% of Americans aged 65 years and older, and these data
reflect health care services used and comorbid health conditions. Hospital-level data
characterize structure and research network affiliation among other factors.
Study Population
The sample included women who were White or African American, aged 65 years or older,
diagnosed in a SEER region with stage I or II breast cancer (ie, the tumor is relatively small
and invasive, but has not spread to other parts of the body) as first or only primary cancer,
for which they received breast-conserving surgery. Those in the sample had complete claims
for 12 months prior through 24 months subsequent to diagnosis. To allow examination of
racial disparities in breast cancer treatment in the context of population heterogeneity,35 the
sample was limited to SEER registries with 5% or greater African Americans. The analysis
was restricted to women receiving some form of axillary staging (either SLNB or ALND),
thus allowing a focus on factors associated with differential utilization of each option, rather
than factors associated with receipt versus nonreceipt of any staging. SLNB was introduced
in the 1990s, though this analysis focused on those diagnosed during 2000 and 2002, to
capture meaningful expansion in this innovation’s use immediately after Medicare’s
approval and initiation of coverage of SLNB in the year 2000, subsequent to the initiation or
completion and positive findings of several relevant clinical trials.16–24
Main Outcome
The primary outcome of interest was the type of lymph node removal procedure used. The
innovation was defined as the receipt of SLNB only or SLNB followed by ALND, because
subsequent ALND might be appropriate, depending on the sentinel pathology results of the
lymph nodes. The alternative categorization was the prior standard of care, defined as
ALND alone. To characterize SLNB, this outcome was assessed in the following 2 ways:
using SEER data (specified sentinel node removal with or without subsequent ALND) and
Medicare billing codes (HCPCS codes for sentinel dye injection procedure or
lymphoscintigraphy). Similarly, patients were categorized as receiving ALND using SEER
data (specified removal of regional lymph nodes with at least 10 nodes examined
[concordant with clinical guidelines for ALND]) and Medicare HCPCS (ALND).
Variables of Interest
Using the SEER-Medicare Provider file, organizational research affiliation was measured as
affiliation with NCI cooperative research groups that have substantial breast cancer clinical
research activity (Eastern Cooperative Oncology Group, Cancer and Leukemia Group B,
Southwest Oncology Group, and National Surgical Adjuvant Breast and Bowel Project).36
Participation in the NCI Cancer Centers program was examined, because these 65 NCI-
designated cancer centers have substantial transdisciplinary cancer research programs.
Affiliation with the American College of Surgeons Oncology Group (ACOSOG) was
measured separately from other cooperative groups for 2 reasons. First, ACOSOG focuses
specifically on cancer surgery research, including studies of SLNB,37 whereas other
cooperative groups focus more on medical research. Second, the majority of ACOSOG sites
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are also accredited by the ACOS Commission on Cancer (CoC), which encourages and
accredits organizations with integrated, programmatic approaches in improving cancer care
quality across a broad spectrum of services and quality measures38; therefore, ACOSOG
affiliation may also be a marker of clinical care quality network affiliation. Teaching status
was measured through medical school affiliation and teaching hospital designation. Breast
cancer-specific surgical volume, an established organizational performance indicator, was
also included.25,28,29,39
Patient-level characteristics include race, age at diagnosis, NCI comorbidity index, and
marital status dichotomized as married or unmarried. Tumor characteristics at diagnosis
include stage, grade, and estrogen receptor status. Census tract-level variables for income
and education were used as indicators of socio-economic status for each patient and assigned
to each patient on the basis of year 2000 data for their area of residence, as done previously.
29
Statistical Methods
Variables were examined in bivariate analyses to assess crude associations between all
variables, to examine functional form, and to ensure that organizational constructs were
independent indicators. Medical school affiliation was highly correlated with all other
organizational variables. Because all NCI centers were also affiliated with cooperative
groups, they saw a very small number of patients (155, or 4%), and because the cooperative
group affiliation measure allows the characterization of clinical research participation in a
broader range of institutions including community hospitals, NCI designation and medical
school affiliation were excluded from subsequent analyses in favor of the organizational
variables reflecting organizational cooperative group affiliation, ACOSOG affiliation,
teaching status, and cancer surgical volume.
To examine organizational differences in innovation diffusion, we used a generalized linear
mixed model with maximum likelihood estimates, implemented through the GLIMMIX
procedure in SAS 9.2 (SAS, 2009). The multilevel model used the logit link function. The
dependent variable was receipt of SLNB with or without ALND versus receipt of ALND
alone. Random effects variables were SEER region and hospitals nested within SEER
region. Fixed effects variables were ACOSOG affiliation, cooperative group affiliation,
volume of breast cancer surgery, year of diagnosis, age, race, within region median income
quartile, and percent of high school education. Predicted probabilities from the adjusted
logistic models were used to construct figures describing the receipt of SLNB over time.
Potential effect modification between the organizational level variables, receipt of SLNB,
and race were examined by stratifying our sample by race and exploring both the main
effects and adjusted models separately.
RESULTS
Although the sample was limited to SEER regions with significant African American
populations, the percentage of African Americans in the sample remained relatively low at
7.7% (Table 1). Most patients received their surgery at an institution affiliated with a
cooperative group (74.1%), a teaching hospital (56.2%), or ACOSOG (36.7%). A large
majority of patients (83.6%) received their care at high-volume institutions. The mean age
for the population was 74.2 years (SD: 5.5), 65.7% had Stage I disease, and the majority was
quite healthy, with two-thirds having a comorbidity index score of 0. In examining crude
associations between organizational factors and SLNB, ACOSOG affiliation and
organizational surgical volume demonstrated the strongest association with a 2-fold greater
probability of SLNB (Table 2).
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In multivariable analysis, the diffusion of SLNB into practice is demonstrated in the
consistently increasing odds of having the procedure between 2000 and 2002 (Table 3).
Compared with patients in 2000, patients were 1.74 times as likely to receive SLNB in 2001
(95% confidence interval [CI]: 1.42–2.13) and 2.70 times as likely in 2002 (95% CI: 2.18–
3.34). Patients were more likely to receive SLNB if their surgery was at a cooperative group
or ACOSOG-affiliated institution (odds ratio [OR]: 1.84, 95% CI: 1.26–2.63; OR: 2.70,
95% CI 1.77–4.12, respectively). After adjustment for these organizational linkage
characteristics, the probability of receiving SLNB was not statistically different among
hospitals with different surgical volumes or among teaching hospitals compared with
nonteaching hospitals. Relative to the youngest women (age, 65–69), women aged 80 years
or older were significantly less likely to receive SLNB (OR: 0.67, 95% CI 0.51–0.87).
Women with more advanced (Stage II) disease were less likely to receive SLNB compared
with women with less-advanced (Stage I) disease. Women with less-aggressive (well-
differentiated) tumors were more likely to receive SLNB than women with aggressive
(poorly differentiated) tumors. The odds of receiving SLNB were significantly lower for
African American women than for White women. There was no effect modification of the
organizational variables by race or race by year in sensitivity analyses (data not shown).
Figure 1 graphically illustrates the progressive increase in the probability of receiving SLNB
over time, as well as the differential probability of receiving SLNB at hospitals with
different organizational affiliations.
DISCUSSION
This study examined whether organizational research and teaching affiliations are associated
with accelerated diffusion of SLNB, an innovation in the treatment of early-stage breast
cancer. Examining a population of breast cancer patients aged 65 years and older, it
demonstrates that modifiable organizational linkages are associated with the diffusion of
evidence-based innovations into clinical practice. Specifically, it was found that women
receiving surgery for early-stage breast cancer at organizations affiliated with NCI
cooperative groups and ACOSOG were more likely to receive the innovative procedure
compared with women treated at other organizations.
These findings provide empirical evidence of a long anecdotally observed association
between organizational clinical research participation and accelerated diffusion of
innovations into evidence-based practice; however, characterizing such associations as
causal is exceedingly challenging, as is most demonstration of causation. These findings
reinforce diffusion theory, which specifies S-shaped diffusion curves that differ between
early adopters and later adopters.32 As presented in Figure 1, we observed nonaffiliated
organizations’ (later adopters) SLNB adoption climbing at a comparatively faster rate (ie, a
steeper slope up the vertical aspect of the “S”), as they catch up to the cooperative group or
ACOSOG-affiliated organizations (earlier adopters) who have passed this point, and whose
adoption rates have begun to plateau. Projections of the curves in Figure 1 suggest that
nonaffiliated organizations are approximately 3 to 5 years behind the “ACOSOG and
Cooperative Group” organizations in their relative adoption of SLNB.
ACOSOG affiliation was found to be the strongest predictor for receipt of SLNB, with
patients experiencing almost 3-fold greater odds of receiving SLNB compared with those
observed at unaffiliated hospitals. ACOSOG’s stronger association compared with the other
cooperative groups suggests a special or distinct nature of this affiliation.37 This measure
might very plausibly also be a marker, connoting the value of these organizations having an
integrated, programmatic approach in improving cancer care quality across a broad spectrum
of services and quality measures.38 Coupling this with research participation among its
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member institutions, surgeons would likely have had direct experience with SLNB (and
other surgical innovations) in their practice, possibly through the controlled setting of a
clinical trial, in a supportive environment with systems to measure and assure clinical care
quality. In addition, these physicians likely had many opportunities for professional
education and training through ACOS, including attendance at national meetings featuring
leaders in the field, which would reinforce the external communication associated with this
affiliation.
Unexpectedly, this study also found that organizational factors previously associated with
cancer care quality and outcomes—-teaching affiliation and surgical volume—-did not
contribute independently to the early adoption of innovative breast cancer treatments. In
bivariate models, the correlations between volume, teaching status, and SLNB use were
positive, and there was a trend of increasing SLNB use with increasing organizational
volume. This suggests the relevance of these measures; however, for this population, it
might be that they were dwarfed by the other factors.
We found that African American and older women were less likely to receive the innovative
and less invasive SLNB procedure. In sensitivity analyses, organizational research affiliation
was associated with slight attenuation in the racial differences in receipt of this state-of-the-
art procedure (data not presented). Findings of lower SLNB utilization among the oldest
patients and among African Americans suggest a troubling persistence of disparities in
receipt of this innovative procedure among those who may benefit most. The slight
attenuation in racial disparities is promising; however, the small sample size of African
Americans and the focus of this study on organizational-level findings precluded more
extensive examination.
Measuring organizational-level characteristics in SEER-Medicare data presents several
challenges. For example, studies have shown that an organization’s Medicare-specific
patient volume and overall patient volume show similar associations with outcomes26;
however, accurately measuring organizational volume for hospitals outside of SEER regions
is difficult. Accurate Medicare volume estimates for such organizations necessitate
Medicare claims for individuals living in those regions, which are under-represented in these
data.
A unique variable specifically characterizing cancer care quality, for example, accreditation
by the ACOS CoC, was not available in these data, and thus represents an opportunity for
future research. In the absence of CoC accreditation, ACOSOG-affiliation may partially
serve as a proxy because most of the ACOSOG-affiliated hospitals are CoC accredited.40
Regarding the overlap among organization-level variables, correlation between ACOSOG
affiliation and (other) cooperative group affiliation was low, and their demonstrated
independence in the model indicates they are indeed indicators of independent constructs,
justifying their independent inclusion.
Finally, generalizability of these findings to younger women is unknown; however, the
importance of the population in this study is not to be underestimated, given that more than
40% of newly diagnosed breast cancer cases occur in women aged 65 years and older.41
CONCLUSIONS
Recent reports of the Institute of Medicine and NCI Operational Efficiency Work Group
have presented the case for change in the NCI Cooperative groups and cooperative group
research42– 43; however, the findings of this study are promising and supportive of the NCI
cooperative groups. Specifically, the findings of this study provide empirical evidence that
beyond success in their primary goal of conducting clinical research, these provider-based
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research networks also play a role in accelerating the translation of research into practice.2,6
Notably, this evidence suggests that the NCI is influential not only in the science of our
national cancer research endeavor, but also in cancer care delivery. For the NCI, the
implications are that it might see value in further support or expansion of programs such as
CCOP to extend its success. For policy-makers, this study illustrates the symbiosis of cancer
clinical research and clinical care, and might cast a new light on coverage policies and
nascent pay-for-performance programs. For example, rather than perpetuating efforts to
separate the funding and management systems for clinical care and clinical research
programs, there may be merit in evaluating systems for their integration.
Although its results are promising, this study also raises a cautionary flag. In addition to
facilitating the adoption of tested and effective innovations, these mechanisms may also
accelerate the adoption of unproven technologies and procedures. Accordingly, further
research should examine how to modulate innovation adoption to accelerate proven
technologies while tempering the adoption of those that are unproven, less effective, or less
safe. It should also expand upon this study’s preliminary findings of attenuation in racial
differences in receipt of SLNB. Confirming these findings would further support the NCI’s
vision of increasing minority accrual into clinical trials as a means of reducing cancer health
disparities.10 While examining these issues, future work should use more granular measures
and enhance generalizability of the findings by studying them among different treatment
modalities. Awaiting confirmation of these findings, institutions may evaluate the
prospective benefits that research participation and ACOSOG affiliation may contribute to
their organizational missions.
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Predicted probability of SLNB by Affiliation Status of Surgical Institution, 2000–2002.
*Adjusted for race, age, marital status, grade, stage, estrogen receptor status, comorbidity
index, census tract education, and income.
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  White 3574 92.3
  Black 300 7.7
 Age
  Age, mean (SD) 74.2 (5.5)
  65–69 yr 941 24.3
  70–74 yr 1183 30.5
  75–79 yr 1071 27.7
  >80 yr 679 17.5
 Stage
  AJCC Stage I 2545 65.7
  AJCC Stage IIA 986 25.5
  AJCC Stage IIB or NOS 343 8.9
 Tumor grade
  Well differentiated 961 24.8
  Moderately differentiated 1586 40.9
  Poorly differentiated 943 24.3
  Unknown, not assessed 384 9.9
 Estrogen receptor status
  Positive 2825 72.9
  Negative 437 11.3
  Unknown 612 15.8
 Comorbidity
  Comorbidity index = 0 2578 66.6
  Comorbidity index >0 1296 33.5
 Year of diagnosis
  2000 1279 33.0
  2001 1281 33.1
  2002 1314 33.9
 Patients with SLNB only 1172 30.3
 Patients with SLNB and subsequent ALND 1468 37.9
 Patients with ALND only 1234 31.9
Organization characteristics (of treating hospital)
 Cooperative group affiliated 2871 74.1
 ACOSOG affiliated 1423 36.7
 Teaching hospital/affiliation 2178 56.2
 NCI cancer center designated 155 4.0
 Volume at treating facility
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No. Patients Percentage
  Tertile 1: patients treated at low volume facility 168 4.3
  Tertile 2: patients treated at mid-volume facility 467 12.1
  Tertile 3: patients treated at high-volume facility 3238 83.6
Environmental characteristics
 SEER region
  San Francisco 224 5.8
  Detroit 683 17.6
  Atlanta and Rural Georgia 271 7.0
  Los Angeles 591 15.3
  Kentucky 470 12.1
  Louisiana 328 8.5
  New Jersey 1307 33.7
 Education: proportion of patient’s census tract population with high school education or greater
  Quartile 1: >75% 984 25.4
  Quartile 2: 51%–75% 978 25.3
  Quartile 3: 26%–50% 955 24.7
  Quartile 4: <25% 952 24.6
 Income: median household income in patient’s census tract
  Quartile 1: low income 933 24.1
  Quartile 2: med-low income 956 24.7
  Quartile 3: med-high income 951 24.6
  Quartile 4: high income 1029 26.6
SD indicates standard deviation; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; ACOSOG, American college of
surgeons oncology group; NCI, national cancer institute; SEER, surveillance epidemiology and end results; AJCC, American Joint Committee on
Cancer; NOS, not otherwise specified.
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TABLE 2
Crude Associations Between SLNB and Organizational Variables in Individual Models
Organizational Variable OR 95% CI
Cooperative group-affiliated 1.96 (1.69–2.28)
ACOSOG-affiliated 2.09 (1.80–2.42)
Teaching hospital/affiliation 1.26 (1.10–1.44)
Breast cancer Medicare volume top tertile (>66.66 percentile) 2.01 (1.69–2.40)
OR indicates odds ratio; CI, confidence interval; SLNB, sentinel lymph node biopsy; ACOSOG, American college of surgeons oncology group.
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TABLE 3
Multivariable Analysis: Probability of Receipt of SLNB Among Early-Stage Breast Cancer Patients
OR 95% CI
Cooperative group-affiliated hospital 1.84 (1.26–2.69)
ACOSOG-affiliated hospital 2.70 (1.77–4.12)
Teaching hospital/affiliation 1.14 (0.79–1.66)
Hospital Medicare breast cancer volume: top tertile (>66.6 percentile; ref = <66.6 percentile) 1.28 (0.97–1.70)
Year of diagnosis (ref = 2000)
 2001 1.74 (1.42–2.13)
 2002 2.70 (2.18–3.34)
Race, African American (ref = white) 0.54 (0.39–0.75)
SEER-modified AJCC stage (ref = Stage I)
 Stage IIA 0.80 (0.66–0.98)
 Stage IIB 0.43 (0.32–0.58)
Age categories (ref = 65–69)
 70–74 0.88 (0.70–1.11)
 75–79 0.83 (0.66–1.06)
 80 yr+ 0.67 (0.51–0.87)
Unmarried (ref = married) 0.88 (0.74–1.05)
Grade (ref = poorly differentiated)
 Unknown, not assessed 1.18 (0.85–1.62)
 Moderately differentiated 1.19 (0.95–1.48)
 Well differentiated 1.35 (1.05–1.75)
Estrogen receptor status (ref = positive)
 Negative 0.81 (0.61–1.06)
 Unknown 1.01 (0.80–1.29)
Education: proportion of patient’s census tract population with high school education or greater (ref = Quartile 4 [most
non-high school graduates, >75 percentile])
 Quartile 1 (Fewest non-high school grads, <25 percentile) 1.00 (0.69–1.44)
 Quartile 2 (25–50 percentile) 1.16 (0.84–1.58)
 Quartile 3 (50–75 percentile) 1.13 (0.87–1.48)
Income: median household income in patient’s census tract (ref = Quartile 4 [top 25% income])
 Quartile 1 (Lowest 25% income) 0.72 (0.50–1.05)
 Quartile 2 (25–50 percentile) 0.84 (0.62–1.15)
 Quartile 3 (50–75 percentile) 0.77 (0.59–1.01)
Comorbidity score (ref = 1+)
 NCI combined comorbidity index 0 0.88 (0.63–1.23)
 NCI combined comorbidity index 0 < 1 0.73 (0.52–1.04)
Intercept Full Difference
Likelihood ratio test of full model vs. intercept only model 4319.67 4045.21 274.46
Df 26
P (based on χ2) P < 0.0001
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Education: proportion of patient’s census tract population with high school education or greater.
OR indicates odds ratio; CI, confidence interval; SLNB, sentinel lymph node biopsy; SEER, Surveillance Epidemiology and End Results; AJCC,
American Joint Committee on Cancer; ACOSOG, American college of surgeons oncology group; NCI, National Cancer Institute.
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